Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

FluoGuide

37.00 SEK

+2.78 %

Less than 1K followers

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.78 %
+3.35 %
+7.87 %
+7.87 %
-5.61 %
+0.95 %
-63.37 %
-68.38 %
+312.70 %

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Read more
Market cap
604.92M SEK
Turnover
103.96K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/5
2026

Interim report Q1'26

25/8
2026

Interim report Q2'26

26/11
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release3/25/2026, 4:44 PM

Minutes from Annual General Meeting in FluoGuide A/S

FluoGuide
Press release3/20/2026, 7:43 AM

BioStock: FluoGuide erhåller FDA fast track-status för FG001 vid höggradigt gliom

FluoGuide
Press release3/20/2026, 7:43 AM

BioStock: FluoGuide receives FDA Fast Track designation for FG001 in high-grade glioma

FluoGuide

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/18/2026, 8:19 PM

FluoGuide receives FDA Fast Track Designation for FG001 in high-grade glioma

FluoGuide
Regulatory press release3/10/2026, 4:50 PM

Notice of Annual General Meeting in FluoGuide A/S

FluoGuide
Press release2/26/2026, 8:45 AM

Redeye: Fluoguide (Q4 Initial take): Key milestones to drive value in 2026

FluoGuide
Press release2/25/2026, 3:33 PM

BioStock: FluoGuide kommenterar rapporten och framtidsplanerna

FluoGuide
Press release2/25/2026, 3:33 PM

BioStock: FluoGuide comments on the annual report and road ahead

FluoGuide
Regulatory press release2/25/2026, 6:09 AM

FluoGuide A/S publishes annual report for the fiscal year 2025

FluoGuide
Regulatory press release2/25/2026, 6:07 AM

FluoGuide A/S publishes interim report for Q4 2025

FluoGuide
Regulatory press release2/20/2026, 7:40 PM

FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track

FluoGuide
Press release2/19/2026, 8:16 AM

Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026

FluoGuide
Press release1/21/2026, 7:21 AM

FluoGuide submits an IND for FG001, to initiate first U.S. registration trial

FluoGuide
Press release12/19/2025, 10:57 AM

FluoGuide updates IND submission timing for FG001 – trial initiation unaffected

FluoGuide
Press release12/3/2025, 10:29 AM

BioStock: FluoGuide understryker operativa framsteg under Q3

FluoGuide
Press release12/3/2025, 10:29 AM

BioStock: FluoGuide highlights operational progress in Q3

FluoGuide
Press release11/27/2025, 6:56 PM

Redeye: FluoGuide (Q3 review) - Busy news flow

FluoGuide
Regulatory press release11/27/2025, 6:18 AM

FluoGuide A/S publishes Interim Report Q3 2025

FluoGuide
Press release11/25/2025, 1:59 PM

FluoGuide signs collaboration agreement with ZEISS

FluoGuide
Regulatory press release11/24/2025, 3:14 PM

Minutes from Extraordinary General Meeting in FluoGuide A/S

FluoGuide
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.